related to the metabolic perturbation, Mendelian disorders, PKU [phenylketonuria] , and things like that.
DG: That's exactly what I'm thinking about. RD: I think in cancer if there is a genetic defect that clearly perturbs metabolism in a way that's closely related to the mechanism of transformation, we are close. I mean, the best example of mutations are IDH1 and IDH2. [ RD: I think that's exactly right. The opportunity in metabolism is how dynamic the network is. It reports so many different things in its response to so many different things.
DG: Only ten years ago people talked about housekeeping genes, and the whole idea about housekeeping genes is they're housekeepers. They don't do anything. They're all steady state, they don't change, and it is a big change to the point of saying . look at GAPDH.
RD: Listen, look at Lew Cantley's talk. He's talking about the Cell paper with Gerburg Wulf, right. What's the message? It's that PI3 kinase basically regulates the liberation of a housekeeping glycolytic enzyme from the microtubule network, which is the ultimate housekeeper. And that's a regulated process.
DG: Of course it is. RD: That basically affects the way cells make energy. DG: Every part of this is. One of the beauties in the metabolism field is that there is so much gold going back 50 years that were fads in the field and then kind of dissipated and reappeared. There's some fantastic literature from 20 or 30 years ago that nobody's even touching. I'm not working on it, but I'm really intrigued by this old literature from the 80s and 90s on channeling.
RD: Metabolic channeling. DG: Metabolic channeling. It's a simple concept, right. Here's the idea. You have a metabolic pathway, so you're going to put in a labeled metabolite and it's going to be converted to its substrate, and it's going to be converted to product down at the very end. It's got the labels in the right places, but here's the really simple idea. You're going to throw in one of the intermediates that's unlabeled, and now you should proportionally remove the label from the end products.
LS: Right, swamp it out. DG: You should be able to enter at any point, and you can't. It doesn't work, and that tells you that there are ways. It's like the supercomplexes in electron transport; there are going to be supercomplexes and metabolic pathways, you watch.
RD: Oh sure. DG: In the next five or ten years, this is going to be a hot area because they're under dynamic regulation.
RD: Right. The idea that Brownian motion somehow is going to account for the fact that you can't put labeled glucose into your cell culture and sample the medium fast enough to avoid to seeing labeled lactate. That somehow every glycolytic intermediate is going to float around and bang into the next enzyme. These things are highly regulated, it's highly organized.
DG: It's channeled. RD: There's literature on the glycosome, basically the ultrastructure of the glycolytic network that we haven't gone back and revisited.
DG: Also especially, how does signaling regulate it? How does it change? There's going to be some really deep biology there, and we're just scratching the surface.
LS: What I'm hearing is that circling back to the old literature is actually going to change what patients see.
DG: They say that three or four weeks in the laboratory can save you hours in the library.
RD: If you're really good at the bench. DG: If you're really good at the bench, you may not have to read for an hour. There is so much gold, especially in this field of metabolism. There is so much gold back there, and instead of disparaging that they didn't have the techniques that we have today or they didn't have the perspective that we have today, pretty much everything you look for is somewhere buried in that literature. As long as you go and read it with an open mind and try to get some information from it. A lot of experiments were done. It's incredible. Most fields don't get that. 
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